SUMMARY Iron is an important catalyst of oxidative radical reactions and promotes the formation of the hydroxyl radical from the superoxide anion radical and hydrogen peroxide. The stimulatory effect of the hydroxyl radical on lipid peroxidation prompted the speculation that free iron may directly promote inflammation and that iron chelating agents may have useful anti-inflammatory properties. This hypothesis is tested in animal models of inflammation with a specific iron chelating agent, desferrioxamine. At low doses (6-6 mg/kg) intraperitoneal desferrioxamine stimulated the induction of acute foot pad swelling in rats by monosodium urate but at higher doses (above 200 mg/kg) it suppressed this inflammatory reaction. A similar anti-inflammatory effect was observed in carrageenan-induced foot pad swelling. In guinea-pigs in which a Glynn-Dumonde synovitis was induced with bovine gammaglobulin, desferrioxamine (100 mg/kg) stimulated the acute inflammatoivy induction phase of this chronic allergic monoarthritis model. Repeated administration of desferrioxamine (100 mg/kg) from the seventh to the twelfth day after intra-articular challenge with bovine gammaglobulin markedly depressed the chronic inflammatory phase. In-vitro experiments suggest that desferrioxamine inhibits iron-catalysed lipid peroxidation when it is poorly saturated with iron, but loses this effect when it is iron saturated. Such an effect may explain our results with desferrioxamine in the animal studies and suggests that effective iron chelation and its removal may modify the inflammatory process in man.
Iron is an important catalyst in biological systems. Its easy access to 2 oxidation states, iron II and iron III, allows it to co-ordinate electron donors and to participate in redox processes. However, this property is potentially hazardous, since reactions involving oxygen favour a univalent reduction pathway which leads to the formation of unstable intermediates with unpaired electrons-free radicals.'
The superoxide radical (02), the Table 1 ). Rats receiving 1 mg desferrioxamine showed a significant increase in swelling compared with the controls at 4 hours (p<005), while 30 mg desferrioxamine had a significant anti-inflammatory effect (p<005). The foot pads of rats receiving 1 mg were considerably redder, with the swelling extending up the hind limb.
In a separate experiment 2 groups of rats received 0-2 mg or 60 mg IP desferrioxamine as above ( Table  1 ). The 0-2 mg dose had no significant effect on foot pad swelling, while the 60 mg dose had a pronounced anti-inflammatory effect (p<0-001). 4, 6 , and 24 hours (see Table 2 ). The 60 mg dose had a significant antiinflammatory effect at all 3 time points, while the 1 mg dose showed / a / significant / anti-inflammatory effect at 24 hours only. Foot pad swelling in this experiment was considerably more than that induced by urate crystals, which might well have masked any potential proinflammatory effect of the lmg dose.
Desferrioxamine Peroxidation of phospholipid liposomes can be induced by ascorbate in a reaction which is inhibited by desferrioxamine (Table 3) . Previous studies have shown that this is due to traces of iron present in the reagent systems.6 Addition of a ferric salt greatly enhanced the ascorbate-dependent peroxidation. When desferrioxamine was added to the lipid before the iron salt, it acted as an effective inhibitor of peroxidation. This inhibitory activity appeared to be greater than that simply accounted for by its known 1:1 molar ferric iron chelating properties. Desferrioxamine mixed with ferric iron before addition to the lipid showed that protective activity is lost when saturation is reached. An equimolar mixture of desferrioxamine and iron III salt showed inhibitory activity toward the ascorbate catalysed peroxidation, suggesting that the desferrioxamine had not been fully saturated under the conditions used for preparation.
Discussion
Desferrioxamine is a chelating agent with an extremely high activity and specificity for Fe III The specificity of the chelating effect of desferrioxamine and the anti-inflammatory effects of this drug on the 3 models described therefore support the original hypothesis that iron may have an important role in the initiation and maintenance of inflammation. However, the short term stimulatory effect of desferrioxamine on inflammation needs further explanation.
Lipid peroxidation is stimulated by both free8 10 and complexed" 12 iron, though the effect of the latter is variable.11 With the iron-binding protein lactoferrin this variability has been shown to relate to the degree of iron saturation. Apolactoferrin, or the partially iron-saturated protein, is an effective inhibitor of hydroxyl radical formation and lipid peroxidation,1' whereas fully iron-saturated lactoferrin can catalyse hydroxyl radical formation.13 Similarly, desferrioxamine inhibits iron-catalysed lipid peroxidation when poorly saturated with iron. This protection appears to be greater than can be accounted for by its iron chelation properties and may suggest a radical scavenging role for this drug.
Mechanisms such as these may in part explain our results with desferrioxamine in the animal studies. The trapping of iron as part of a poorly saturated desferrioxamine complex would inhibit ironcatalysed damage and lipid peroxidation and thereby suppress the inflammatory response. This inhibitory effect would be expected to occur if relatively high doses of desferrioxamine were available at the inflammatory site or if the ferrioxamine had been excreted. In contrast, low doses of desferrioxamine would rapidly become iron saturated and lose its protecting properties against iron catalysed lipid peroxidation.
The results of these experiments suggest that effective iron chelation and its removal may prove a useful way of modifying the inflammatory process in man. It may be particularly appropriate to the treatment of rheumatoid disease, where iron is concentrated in the synovial membrane'4 and where there are large numbers of activated polymorphonuclear cells releasing oxygen-free radicals, but no free radical scavengers, within the synovial fluid. '5 inflammation.
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